ATE545657T1 - Tgf-beta antikörper - Google Patents

Tgf-beta antikörper

Info

Publication number
ATE545657T1
ATE545657T1 AT06840328T AT06840328T ATE545657T1 AT E545657 T1 ATE545657 T1 AT E545657T1 AT 06840328 T AT06840328 T AT 06840328T AT 06840328 T AT06840328 T AT 06840328T AT E545657 T1 ATE545657 T1 AT E545657T1
Authority
AT
Austria
Prior art keywords
tgf
beta antibodies
antibodies
mammal
antigen
Prior art date
Application number
AT06840328T
Other languages
English (en)
Inventor
Bryan Jones
James Pancook
Scott Rowlinson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE545657T1 publication Critical patent/ATE545657T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06840328T 2005-12-23 2006-12-20 Tgf-beta antikörper ATE545657T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75395605P 2005-12-23 2005-12-23
PCT/US2006/062397 WO2007076391A1 (en) 2005-12-23 2006-12-20 Tgf-beta binding compositions

Publications (1)

Publication Number Publication Date
ATE545657T1 true ATE545657T1 (de) 2012-03-15

Family

ID=37898733

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06840328T ATE545657T1 (de) 2005-12-23 2006-12-20 Tgf-beta antikörper

Country Status (10)

Country Link
US (3) US7494651B2 (de)
EP (1) EP1966243B1 (de)
JP (1) JP2009521496A (de)
CN (1) CN101346394B (de)
AT (1) ATE545657T1 (de)
AU (1) AU2006330542B2 (de)
BR (1) BRPI0620240A2 (de)
CA (1) CA2632799A1 (de)
ES (1) ES2379194T3 (de)
WO (1) WO2007076391A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097832A2 (en) * 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
ES2379194T3 (es) * 2005-12-23 2012-04-23 Eli Lilly And Company Anticuerpos de unión a TGF-beta
US8350006B2 (en) * 2008-10-24 2013-01-08 Mead Johnson Nutrition Company Methods for determining the bioactivity of TGF-β in a composition
WO2010080910A1 (en) * 2009-01-08 2010-07-15 Bio-Rad Laboratories, Inc. Methods and compositions for improving efficiency of nucleic acids amplification reactions
ES2702049T3 (es) * 2009-04-24 2019-02-27 Univ Vanderbilt Inducción anti-TGF-beta de crecimiento óseo
EP2714735B1 (de) 2011-06-03 2021-07-21 XOMA Technology Ltd. Tgf-beta-spezifische antikörper
US9518112B2 (en) 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
US10259626B2 (en) 2012-03-08 2019-04-16 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
DK2976359T4 (da) * 2013-03-20 2022-06-13 Genzyme Corp Fremgangsmåder til behandling af osteogenesis imperfecta
WO2016024628A1 (ja) * 2014-08-14 2016-02-18 学校法人東京医科大学 樹状細胞の抗癌免疫賦活能の促進方法およびその用途
CA2973978A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
WO2016161410A2 (en) 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
EP3307772B1 (de) 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta-3-spezifische antikörper und verfahren sowie verwendungen davon
JP7359547B2 (ja) 2016-05-17 2023-10-11 ジェネンテック， インコーポレイテッド 免疫療法における診断及び使用のための間質遺伝子シグネチャー
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
TW201923089A (zh) 2017-11-06 2019-06-16 美商建南德克公司 癌症之診斷及治療方法
WO2020006509A1 (en) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor antagonists
WO2020095113A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
EP3877053A1 (de) 2018-11-05 2021-09-15 Ludwig Institute for Cancer Research Ltd Humanisierte und variante tgf-beta3-spezifische antikörper sowie verfahren und verwendungen davon
WO2020263312A1 (en) 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
WO2021021991A1 (en) 2019-08-01 2021-02-04 Vaccinex,Inc. Combined inhibition of semaphorin-4d and tgfb and compositions therefor
JP2023514324A (ja) 2020-02-19 2023-04-05 ナミ セラピューティクス， インコーポレイテッド がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2022109443A1 (en) * 2020-11-23 2022-05-27 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
EP4251645A1 (de) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Mit signalmodulatoren manipulierte zelluläre therapeutika und verfahren zur verwendung davon
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
CN115707716A (zh) * 2021-08-18 2023-02-21 丹生医药技术(上海)有限公司 一种TGF-β/VEGF双功能抗体融合蛋白
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
ES2379194T3 (es) * 2005-12-23 2012-04-23 Eli Lilly And Company Anticuerpos de unión a TGF-beta

Also Published As

Publication number Publication date
WO2007076391A9 (en) 2008-08-28
ES2379194T3 (es) 2012-04-23
BRPI0620240A2 (pt) 2011-11-08
US20080292638A1 (en) 2008-11-27
CN101346394A (zh) 2009-01-14
US7494651B2 (en) 2009-02-24
US20100136021A1 (en) 2010-06-03
EP1966243B1 (de) 2012-02-15
AU2006330542B2 (en) 2012-05-24
CN101346394B (zh) 2012-07-25
WO2007076391A1 (en) 2007-07-05
US20090155285A1 (en) 2009-06-18
JP2009521496A (ja) 2009-06-04
US7927593B2 (en) 2011-04-19
EP1966243A1 (de) 2008-09-10
AU2006330542A1 (en) 2007-07-05
CA2632799A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
ATE545657T1 (de) Tgf-beta antikörper
CY1120365T1 (el) Αντισωματα εναντι της il-17
HK1116803A1 (en) Novel anti-plgf antibody
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
NO2017032I1 (no) bezlotoksumab
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
ATE526987T1 (de) Dr5-antikörper und deren verwendung
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
UA92504C2 (en) Anti-myostatin monoclonal antibody
DK2135881T3 (da) Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
WO2006118772A3 (en) Fcrn antibodies and uses thereof
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
DE602006013029D1 (de) Anti-egfr-antikörper
DK1706424T3 (da) FC-region varianter
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
WO2008085878A3 (en) High affinity antibodies that neutralize staphylcoccus enterotoxin b
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon
WO2007038407A3 (en) Compositions and methods for treating nervous system disorders
TW200738236A (en) Certain chemical entities, compositions, and methods
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13
UA94245C2 (en) Anti-il-17 antibodies